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Background-—Time in therapeutic range (TTR) is a standard quality measure of the use of warfarin. We assessed the relative
effects of rivaroxaban versus warfarin at the level of trial center TTR (cTTR) since such analysis preserves randomized comparisons.
Methods and Results-—TTR was calculated using the Rosendaal method, without exclusion of international normalized ratio (INR)
values performed during warfarin initiation. Measurements during warfarin interruptions >7 days were excluded. INRs were
performed via standardized ﬁnger-stick point-of-care devices at least every 4 weeks. The primary efﬁcacy endpoint (stroke or non-
central nervous system embolism) was examined by quartiles of cTTR and by cTTR as a continuous function. Centers with the
highest cTTRs by quartile had lower-risk patients as reﬂected by lower CHADS2 scores (P<0.0001) and a lower prevalence of prior
stroke or transient ischemic attack (P<0.0001). Sites with higher cTTR were predominantly from North America and Western
Europe. The treatment effect of rivaroxaban versus warfarin on the primary endpoint was consistent across a wide range of cTTRs
(P value for interaction=0.71). The hazard of major and non-major clinically relevant bleeding increased with cTTR (P for
interaction=0.001), however, the estimated reduction by rivaroxaban compared with warfarin in the hazard of intracranial
hemorrhage was preserved across a wide range of threshold cTTR values.
Conclusions-—The treatment effect of rivaroxaban compared with warfarin for the prevention of stroke and systemic embolism is
consistent regardless of cTTR. (J Am Heart Assoc. 2014;3:e000521 doi: 10.1161/JAHA.113.000521)
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V
itamin K antagonists (VKAs) have formed the basis for
the prevention of stroke and systemic embolus in
patients with atrial ﬁbrillation (AF) for several decades.
1 The
major impediment to VKA use is the unpredictability of the
level of anticoagulation at a given dose. The international
normalized ratio (INR) has been introduced as a measure of
anticoagulation that enables the clinician and patient to
monitor the degree of anticoagulation when VKAs are used.
When the INR is <1.8 the risk of stroke and systemic
embolism increases, and when the INR is >3.5 the risk of
bleeding increases.
2 This range includes the standard range
of INR 2.0 to 3.0 widely recommended for VKA treatment
for patients with AF.
3,4
The estimated time in the therapeutic range (TTR) of INR
2.0 to 3.0 has become a widely applied measure of the quality
of VKA anticoagulation in patients with AF, with most studies
using Rosendaal’s interpolation method of calculating TTR.
5
Several studies have shown a direct relationship between TTR
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ORIGINAL RESEARCHand lower rates of stroke and systemic embolism in patients
with AF, while the relationship to bleeding risk has been more
variable.
6,7 The ROCKET AF (Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared with Vitamin K Antag-
onism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation) trial had a prospective analysis plan to estimate
the relationship between TTR and the treatment effect of
rivaroxaban compared with warfarin.
ROCKET AF was a blinded randomized trial that directly
compared warfarin treatment with a novel factor Xa inhibitor,
rivaroxaban.
8 While TTR was measurable in the warfarin-
treated participants in the ROCKET AF trial, it is not an
appropriate measure of anticoagulation in patients treated
with factor Xa inhibitors. As a result, it becomes problematic
to compare rivaroxaban-treated patients with warfarin-treated
patients who are grouped by individual-level TTR values. The
ROCKET AF trial prespeciﬁed the alternative approach of
comparing the treatment effects of rivaroxaban versus
warfarin stratiﬁed by center-level TTR, thereby preserving
randomized comparisons.
Methods
Trial Design
The design and primary results of ROCKET AF have been
published.
8,9 In brief, ROCKET AF was a multicenter, random-
ized, double-blind, double-dummy, event-driven trial comparing
rivaroxaban 20 mg daily (or 15 mg daily in patients with
creatinine clearance 30 to 49 mL/min) with dose-adjusted
warfarin (target INR 2.0 to 3.0) for prevention of all stroke
(ischemic or hemorrhagic) and systemic embolism.
9 A double-
blind design was chosen to minimize bias in co-interventions
and reporting of clinical events. To maintain blinding, the
INRatio(HemoSense)point-of-caredevicewasusedtogenerate
real INR or sham values. The sham INR results were generated
usingavalidatedalgorithmthatreﬂectedthedistributionofINR
values in a population of patients taking warfarin with clinical
characteristics similar to the study population.
9 The doses of
warfarin and matching placebo tablets were titrated by the
investigators based on these values.
9
The trial was supported by research grants from Johnson &
Johnson Pharmaceutical Research & Development and Bayer
HealthCare AG. The Duke Clinical Research Institute in
Durham, NC coordinated the trial and performed the statis-
tical analyses for this manuscript independent of the spon-
sors. All appropriate national regulatory agencies and ethics/
institutional review boards at each participating center
approved the study. An international, multispecialty executive
committee, designed the study and takes responsibility for
the accuracy and completeness of all data and subsequent
analyses.
Measurement of INR
The INR was measured prior to randomization. Subjects were
randomized when the INR was <3.0. Post-randomization INR
monitoring was performed using the blinded point-of-care
device. The ROCKET AF protocol recommended that INR
monitoring be performed as clinically indicated, but no less
frequently than every 4 weeks.
Calculation of TTR
We present TTR using the method of Rosendaal and
colleagues, without exclusion of INR values obtained during
the period at the start of study-assigned warfarin therapy or
during temporary discontinuations.
5 We present analyses
according to center TTR (cTTR) where cTTR was calculated as
the percent of all INR values at each center that fell within the
therapeutic range (2.0 to 3.0).
Statistical Methods
Baseline characteristics are shown as median (25th, 75th
percentiles) for continuous variables and as percent (num-
ber) for categorical variables, and were compared among
cTTR quartiles using Kruskal-Wallis tests for continuous
variables and Pearson chi-square tests for categorical
variables.
The risk of outcomes for patients randomized to rivarox-
aban versus warfarin was assessed using Cox proportional
hazards models with treatment as a covariate and using
robust sandwich variance estimators to account for correla-
tion within centers. All analyses were done in the safety on-
treatment population. The on-treatment period was deﬁned as
the period during which the study drug was taken plus 2 days
following permanent study drug discontinuation (ie, from ﬁrst
study drug dose to last dose plus 2 days). Safety analyses
included patients from a good clinical practice (GCP)-violating
site while efﬁcacy analyses excluded these patients (n=93).
Risk relationships within regions or within cTTR quartiles were
generated using models within those subgroups. The geo-
graphic regions were the same as those described in the main
trial results.
8 Comparison of these risk relationships across
cTTR quartiles was achieved using a model that contained
treatment, cTTR quartile, and their interaction. For further
examination of the association of risk relationship to cTTR, a
series of models was generated at different cTTR thresholds,
ie, among all centers with cTTR at or above a certain value,
ranging from 0% to 80%. All models were adjusted for
geographic region, except subgroup models within regions.
Risk relationships are expressed as hazard ratios with 95%
conﬁdence intervals. The probability of having an event by
1 year was also derived from the Cox models.
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Baseline Characteristics
ROCKET AF enrolled a high-risk population with many risk
factors for stroke and systemic embolism. Among the 14 264
randomized patients, the median age was 73 years, mean
CHADS2 score was 3.5, 55% had prior thromboembolism, and
62.5% had heart failure. Among the 7133 randomized to
warfarin, 7025 had INR data and the mean individual TTR in
warfarin patients was 55%. The distribution of cTTR across all
sites is shown in Figure 1. The mean cTTR was 59% and the
median was 61% (25th, 75th: 51%, 69%). The baseline
characteristics of the patients according to quartiles of cTTR
are shown in Table 1. Centers with higher cTTR had lower-risk
patients as evidenced by lower CHADS2 scores (P<0.0001)
and a lower prevalence of prior stroke or transient ischemic
attack (TIA) (P<0.0001). Centers with higher cTTR were from
regions with middle- and high-income countries, including
Western Europe and North America.
Geographic Variation in cTTR
The mean cTTR varied across geographic regions, as shown in
Table 2. The highest mean cTTR occurred in North America
(65%) and the lowest was observed in the Asia-Paciﬁc region
and Eastern Europe (52%).
Outcomes and cTTR
The primary efﬁcacy outcome (stroke or non-central nervous
system [CNS] embolism) for rivaroxaban versus warfarin is
shown across the quartiles of cTTR in Table 3. Rates of stroke
or non-CNS embolism decreased with higher cTTR. The
treatment effect with rivaroxaban on the primary endpoint
across cTTR quartiles was consistent (P for interaction=0.71).
The hazard ratio (HR) for the primary efﬁcacy endpoint was
0.70 (95% conﬁdence interval [CI] 0.47 to 1.04) in the lowest
quartile of cTTR and 0.73 (0.50 to 1.06) in the highest quartile
of cTTR. We repeated these analyses for the endpoint of
ischemic stroke or non-CNS systemic embolism and the
results again showed no evidence of heterogeneity across
cTTR quartiles (Table 4, interaction P=0.86).
The lowest HR for the primary endpoint (rivaroxaban versus
warfarin) was observed in the region with the highest cTTR
(North America HR 0.61 [95% CI 0.35 to 1.06]). There was no
evidence of an interaction between region and treatment
(P for interaction=0.62).
As shown in Table 5, the rates of the primary safety
endpoint (major and non-major clinically relevant bleeding)
increased with higher cTTR. In the lowest quartile of cTTR,
rivaroxaban was associated with a lower hazard of bleeding
(HR 0.80 [95% CI 0.66 to 0.98]), while in the top quartile of
cTTR, rivaroxaban was associated with a higher hazard
0
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Figure 1. Distribution of cTTR across all sites. This histogram illustrates the distribution of the sites according to cTTR. cTTR indicates center
time in therapeutic range; INR, international normalized ratio.
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Baseline Characteristics
cTTR Q1
(0.0% to 50.6%)
(N=3430)
cTTR Q2
(50.7% to 58.5%)
(N=3563)
cTTR Q3
(58.6% to 65.7%)
(N=3496)
cTTR Q4
(65.7% to 100%)
(N=3508) P Value
Age, y 70 (62, 76) 72 (64, 77) 74 (66, 78) 75 (68, 80) <0.0001
Female 44% (1506) 41% (1450) 39% (1368) 35% (1222) <0.0001
Race <0.0001
White 73% (2490) 85% (3011) 83% (2904) 92% (3231)
Black 1% (33) 2% (56) 2% (55) 1% (34)
Asian 22% (767) 11% (393) 13% (441) 5% (169)
Other 4% (140) 3% (103) 3% (96) 2% (74)
Region <0.0001
Asia/Pacific Islands 22% (766) 11% (405) 13% (462) 13% (455)
Eastern Europe 57% (1947) 50% (1797) 35% (1210) 12% (426)
Latin America 11% (378) 16% (556) 16% (573) 10% (359)
North America 5% (182) 12% (417) 17% (592) 40% (1417)
Western Europe 5% (157) 11% (388) 19% (659) 24% (851)
BMI, kg/m
2 27.7 (24.7, 31.6) 28.2 (25.1, 31.8) 28.3 (25.1, 32.0) 28.7 (25.6, 32.6) <0.0001
Systolic BP, mean (SD) 132.7 (15.6) 132.2 (15.9) 132.1 (16.4) 131.6 (17.1) 0.0031
AF type 0.0001
Persistent 81% (2788) 82% (2930) 79% (2761) 82% (2868)
Paroxysmal 18% (604) 17% (600) 20% (685) 16% (575)
New onset 1% (38) 1% (33) 1% (50) 2% (65)
Hypertension 90% (3100) 92% (3276) 91% (3180) 89% (3115) <0.0001
Diabetes 37% (1262) 39% (1385) 42% (1454) 42% (1460) <0.0001
Prior stroke or TIA 58% (1995) 53% (1891) 51% (1798) 47% (1657) <0.0001
CHF 71% (2448) 70% (2478) 61% (2129) 49% (1711) <0.0001
eGFR (MDRD) 69.4 (57.1, 81.0) 68.6 (56.7, 81.6) 66.6 (55.9, 78.5) 68.4 (56.3, 78.7) <0.0001
Hemoglobin, g/dL 14.3 (13.2, 15.4) 14.2 (13.2, 15.2) 14.2 (13.1, 15.2) 14.1 (13.1, 15.1) <0.0001
CAD 20% (686) 21% (754) 23% (816) 29% (1018) <0.0001
COPD 10% (347) 10% (345) 10% (348) 12% (417) 0.010
PAD 6% (193) 5% (169) 6% (227) 6% (227) 0.0039
Prior GI bleed 2% (80) 2% (60) 4% (151) 6% (195) <0.0001
Liver disease 7% (252) 4% (158) 5% (187) 4% (137) <0.0001
Alcohol consumption (past 12 months) <0.0001
Abstinent 75% (2586) 69% (2454) 64% (2227) 51% (1793)
Light 22% (747) 27% (956) 31% (1096) 41% (1430)
Moderate 2% (71) 3% (122) 4% (147) 7% (263)
Heavy 1% (26) 1% (31) 1% (25) 1% (21)
CHADS2, mean (SD) 3.5 (0.9) 3.5 (0.9) 3.5 (1.0) 3.3 (1.0) <0.0001
CHADS2 score <0.0001
2 11% (364) 11% (383) 13% (446) 18% (641)
3 42% (1456) 45% (1597) 43% (1511) 44% (1541)
4 32% (1102) 29% (1035) 29% (1006) 25% (872)
5 13% (456) 14% (484) 13% (444) 11% (384)
6 2% (52) 2% (64) 3% (89) 2% (70)
VKA use at screening 41% (1403) 56% (1998) 69% (2400) 83% (2925) <0.0001
Chronic aspirin at screening 45% (1542) 41% (1446) 32% (1127) 29% (1005) <0.0001
Continuous variables are shown as median (25th, 75th percentiles), except where noted. Categorical variables are shown as percent (number). P value is from Pearson chi-square test for
categorical variables, from Kruskal-Wallis test for continuous variables. AF indicates atrial ﬁbrillation; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CHF,
congestive heart failure; COPD, chronic obstructive pulmonary disease; cTTR, center-level time in therapeutic range; eGFR, glomerular ﬁltration rate; GI, gastrointestinal; MDRD,
Modiﬁcation of Diet in Renal Disease; PAD, peripheral arterial disease; SD, standard deviation; TIA, transient ischemic attack; VKA, Vitamin K antagonist.
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interaction=0.001).
Figure 2 displays the modeled risk of stroke or non-CNS
embolism, with 95% conﬁdence limits, according to treatment
assignment (rivaroxaban or warfarin) and cTTR viewed as a
continuous variable. Centers with higher cTTR values had a
lower risk of stroke and non-CNS embolism in both rivarox-
aban- and warfarin-treated patients. Figure 3 illustrates the
treatment effect (rivaroxaban versus warfarin) at increasing
thresholds of cTTR. The treatment effect was relatively
consistent across the range of cTTR values. Figure 4 provides
the same display for the endpoint of intracranial hemorrhage.
The estimated reduction in the hazard of intracranial hemor-
rhage was preserved across a wide range of threshold cTTR
values. There is no evidence that the beneﬁt of rivaroxaban for
prevention of intracranial bleeding is lost at any level of cTTR
(Figure 4).
Discussion
TTR is a widely used measure of quality of anticoagulation
with warfarin. In the ROCKET AF trial the TTR correlated
negatively with risk of stroke and systemic embolism,
although TTR correlated positively with risk of bleeding.
However, despite a wide variation of TTR levels across centers
in the trial there was no evidence that the relative efﬁcacy of
rivaroxaban versus warfarin varied by cTTR.
TTR is impacted by a host of factors.
7,10 Multiple
comorbidities such as heart failure, liver and lung disease,
and renal disease can alter INR control.
11 While none of these
individually have a major impact on TTR, in aggregate they
have a signiﬁcant impact. Perhaps more important is the
adherence of the patient, which is dependent on many social,
cultural, ﬁnancial, and individual behavioral characteristics in
addition to the direction of the prescriber.
12,13 Some studies
have shown that instrumental factors such as distance
between the clinic and home and availability of transportation
are important. We recently published the ﬁnding that the
region, and more importantly, the country involved has a
major impact on TTR, far outweighing all the other factors
routinely measured in clinical practice or clinical trials.
10 A
recent analysis from the RE-LY (Randomized Evaluation of
Long-Term Anticoagulation Therapy) trial found that much of
the variation in cTTR values could be explained by whether
or not an algorithmic approach to warfarin management was
used.
14
The relationships among TTR, outcomes, and treatment
effect in the ROCKET AF trial cannot be directly assessed at
the individual patient level using iTTR since it is not
meaningful in patients treated with rivaroxaban. Furthermore,
because TTR is a post-randomization covariate, patients with
different TTR levels are likely to have different levels of stroke
and bleeding risk independent of TTR. Identifying appropriate
comparator patients assigned to rivaroxaban (for whom INR
values are not available) is not possible with suitable
accuracy, so using it to adjust the estimate of treatment
effect violates usual principles of analysis and abrogates the
advantages gained by randomization.
15 Because of these
concerns, we and others have compared patients assigned to
Table 2. Mean cTTR and Treatment Effect Across Geographic
Regions
Region Mean TTR (%)
Primary Efﬁcacy Endpoint
(Safety On-Treatment Population)
HR (95% CI)
North America 65 0.61 (0.35, 1.06)
Western Europe 64 0.87 (0.52, 1.46)
Latin America 57 0.93 (0.62, 1.37)
Asia/Pacific Islands 52 0.67 (0.44, 1.03)
Eastern Europe 52 0.88 (0.67, 1.19)
CI indicates conﬁdence interval; cTTR, center-level time in therapeutic range; HR, hazard
ratio.
Table 3. Stroke and Non-CNS Embolism by Quartiles of cTTR
Center TTR
Rivaroxaban (N=6891) Warfarin (N=7080) Rivaroxaban vs Warfarin
n/J (%)
Event Rate
(100 Pt-Years) n/J (%)
Event Rate
(100 Pt-Years) HR (95% CI)
Interaction
P Value*
0.00% to 50.6% 45/1735 (2.6) 1.8 62/1689 (3.7) 2.5 0.70 (0.47, 1.04) 0.709
50.7% to 58.5% 53/1746 (3.0) 1.9 63/1807 (3.5) 2.2 0.90 (0.64, 1.26)
58.6% to 65.7% 54/1734 (3.1) 1.9 62/1758 (3.5) 2.1 0.88 (0.62, 1.25)
65.7% to 100.0% 37/1676 (2.2) 1.3 55/1826 (3.0) 1.8 0.73 (0.50, 1.06)
The population for this analysis was the safety on-treatment population from sites with calculable cTTR. cTTR was calculated from all ITT warfarin patients at each center. All analyses are
based on the time to ﬁrst event. Event rates are the number of events per 100 patient-years of follow-up. HRs (95% CIs) are derived from a proportional hazards model with treatment as a
covariate. CNS indicates central nervous system; cTTR, center-level time in therapeutic range; J, number of subjects in each subgroup; n, number of subjects with events.
*The P value for the interaction of treatment group and center-based INR control group based on the Cox proportional hazard model including treatment group, center-based INR control
group, and their interaction.
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the analysis still beneﬁts from randomization.
16 However,
analysis at the center level allows only indirect inference
about the effect of individual-level TTR, ie, iTTR. Moreover, our
analysis demonstrated that centers with higher cTTR have
patients with different comorbidity proﬁles, including lower-
risk patients as indicated by lower CHADS2 scores and lower
event rates even among the centers’ patients taking rivarox-
aban.
While we saw no overall relationship between cTTR and the
relative effect of rivaroxaban versus warfarin, we did not have
sufﬁcient power to speciﬁcally examine centers achieving TTR
levels above 70. Analyses from the large RE-LY and
ARISTOTLE (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation) trials also found
no relationship between cTTR and the estimate of the
treatment effect, including sites with cTTR >70.
16,17
The increase in bleeding that we observed in centers with
higher cTTR levels is consistent with higher INR levels seen in
such centers. Worldwide in centers with poor TTR, the most
common deviation is almost always with persistent low values
rather than high values. This likely explains the preservation of
the beneﬁt for intracranial hemorrhage regardless of cTTR.
Some regions of the world have more aversion to bleeding
than others leading to more cautious adjustments to VKA
doses.
18,19
One consideration in understanding the cTTR values is the
actual observed event rates in the trial on warfarin therapy. In
ROCKET AF, the observed event rates for a CHADS2 score of 2
was 1.7, for CHADS2 score of ≥3 was 2.6, and for prior stroke
patients was 2.9 events per 100 patient-years versus 1.4,
2.8, and 3.2 in the ARISTOTLE trial which had a higher TTR on
average. These data provide additional support for the
concept that cTTR depends on a complex mix of factors,
with practitioner skill being only one of them. For example,
simply measuring more INRs will lead to a higher TTR,
assuming that appropriate changes in doses are made. In
countries with closer proximity of clinics to patients and with
fewer cost constraints, INRs tend to be measured more
frequently.
The question of whether there is a cTTR that is too low
to allow for a valid direct comparison of a new anticoag-
Table 4. Ischemic Stroke or Non-CNS Systemic Embolism by Quartiles of cTTR
Center TTR
Rivaroxaban (N=6891) Warfarin (N=7080) Rivaroxaban vs Warfarin
n/J (%)
Event Rate
(100 Pt-Year) n/J (%)
Event Rate
(100 Pt-Year) Hazard Ratio (95% CI)
Interaction
P Value*
0.00% to 50.6% 38/1735 (2.2) 1.5 49/1689 (2.9) 2.0 0.75 (0.48, 1.16) 0.863
50.7% to 58.5% 40/1746 (2.3) 1.5 46/1807 (2.6) 1.6 0.93 (0.61, 1.41)
58.6% to 65.7% 43/1734 (2.5) 1.5 46/1758 (2.6) 1.6 0.95 (0.66, 1.40)
65.7% to 100.0% 33/1676 (2.0) 1.2 41/1826 (2.3) 1.3 0.87 (0.58, 1.32)
The population for this analysis was the safety on-treatment population from sites with calculable cTTR. cTTR was calculated from all ITT warfarin patients at each center. All analyses are
based on the time to ﬁrst event. Event rates are the number of events per 100 patient-years of follow-up. HRs (95% CIs) are derived from a proportional hazards model with treatment as a
covariate. CNS indicates central nervous system; cTTR, center-level time in therapeutic range; J, number of subjects in each subgroup; n, number of subjects with events.
*The P value for the interaction of treatment group and center-based INR control group based on the Cox proportional hazard model including treatment group, center-based INR control
group, and their interaction.
Table 5. Major and Non-Major Clinically Relevant Bleeding by Quartiles of cTTR
Center TTR
Rivaroxaban (N=6941) Warfarin (N=7123) Rivaroxaban vs Warfarin
n/J (%)
Event Rate
(100 Pt-Years) n/J (%)
Event Rate
(100 Pt-Years) HR (95% CI)
Interaction
P Value*
0.00% to 50.71% 271/1780 (15.2) 11.30 315/1734 (18.2) 14.12 0.80 (0.66, 0.98) 0.001*
50.89% to 58.44% 285/1731 (16.5) 11.72 313/1785 (17.5) 12.21 0.96 (0.81, 1.14)
58.46% to 65.66% 381/1741 (21.9) 15.10 378/1765 (21.4) 14.88 1.03 (0.87, 1.22)
65.71% to 100.0% 484/1689 (28.7) 20.61 443/1839 (24.1) 16.72 1.25 (1.10, 1.41)
The population for this analysis was safety on-treatment patients from sites with calculable cTTR. cTTR was calculated from all safety warfarin patients at each center. Therefore, the
quartiles are slightly different from Table 3. All analyses are based on the time to ﬁrst event. Event rates are number of events per 100 patient-years of follow-up. HRs (95% CIs) are derived
from a proportional hazard model with treatment as a covariate. cTTR indicates center-level time in therapeutic range; J, number of subjects in each subgroup; n, number of subjects with
events.
*The P value for the interaction of treatment group and center-based INR control group based on the Cox proportional hazard model including treatment group, center-based INR control
group, and their interaction.
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Hulant with warfarin merits serious consideration. At the
extreme, if cTTR was very low, one would expect the
comparator treatment to be superior if it was effective.
While no direct measure of TTR was available in most of the
controlled trials of warfarin in AF, best estimates using
meta-analysis indicate a TTR in the range of 61%.
20 The
average TTR in US practice is 55% and recent data indicate
that in clinical practice, TTR values are typically below
60%.
2,21 Furthermore, the region with the highest TTR
(North America), had the largest point estimate for treat-
ment difference in favor of rivaroxaban, a ﬁnding that was
not statistically signiﬁcant, but the existing trend favors no
impact of cTTR on estimates of the rivaroxaban treatment
effect.
Limitations
The limitations of this analysis should be considered. These
results emanate from a randomized, blinded trial at
selected centers in a high-risk population. TTR is a post-
randomization variable and therefore, the entire analysis
has uncertainties and should be considered to provide a
perspective akin to a sensitivity analysis. Furthermore, the
analysis of cTTR in this study and in other trials has limited
power.
Conclusion
TTR is an important and validated quality measure for VKA
management. However, TTR does not impact the estimate of
the treatment effect of rivaroxaban versus warfarin for the
prevention of stroke and systemic embolism. The consistency
of this ﬁnding with other major trials of novel anticoagulants
versus warfarin
16,17 and the observation of expected event
rates on warfarin treatment in ROCKET AF provide support for
this conclusion. Regardless of the choice of anticoagulation,
adherence factors related to education, cultural factors,
economics, and transportation need to be considered in
designing systems of care for stroke prevention as well as
medical comorbidities and access to expert medical care from
skilled clinicians.
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Figure 2. Probability of stroke or non-CNS embolism in rivaroxaban and warfarin treated patients according to
cTTR. cTTR is shown on the x-axis. Probability of stroke or non-CNS embolism by 1-year of follow-up is shown on the
y-axis. This plot shows the probability of having a stroke or non-CNS embolism according to cTTR for rivaroxaban-
and warfarin-treated patients (solid lines) with corresponding 95% CIs (dashed lines). Centers with higher cTTR
values had a lower risk of stroke and systemic embolus in both the rivaroxaban- and warfarin-treated arms. CNS
indicates central nervous system; cTTR, center time in therapeutic range; INR, international normalized ratio.
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Figure 3. Treatment effect for the reduction of stroke or non-CNS embolism in rivaroxaban and warfarin treated
patients at a given cTTR threshold. The x-axis shows the threshold value for cTTR and the y-axis shows the HR for the
time to stroke or non-CNS embolism for rivaroxaban vs warfarin given a certain threshold cTTR. The y-axis also shows
the mean individual TTR in those centers that meet the threshold cTTR. There is instability in the estimate of the
treatment effect at high cTTR thresholds due to smaller sample size, but no evidence that warfarin is superior to
rivaroxaban in the prevention of stroke and systemic embolus at any cTTR threshold. CNS indicates central nervous
system; cTTR, center time in therapeutic range; INR, international normalized ratio.
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